Prepayments (CK93) - Nykredit Realkredit A/S
To the Nasdaq Copenhagen
Pursuant to s 24 of the Danish Capital Markets Act, Nykredit Realkredit A/S hereby publishes prepayment data (CK93) as at 13 October 2023 in the attached file.
Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/.
For further information about data format and contents, please refer to the Nasdaq website.
Questions may be addressed to Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21.
Nykredit Realkredit A/S
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Borregaard ASA: Reporting of transactions in Borregaard ASA's shares made by person discharging managerial responsibilities27.2.2024 12:04:09 CET | Press release
27.02.24: Borregaard ASA ("Borregaard", OSE ticker: BRG) Borregaard's Board of Directors has issued share options in accordance with the proxy given by the Annual General Meeting held on 18 April 2023. The total number of options issued is 371,000. The options will expire after five years (27 February 2029) and may be exercised in the last two years. The strike price of the options is NOK 199.10. It is based on the volume weighted average share price (VWAP) during the first three trading days after the announcement of the 4th quarter 2023 results with an addition of 10%. The strike price will be adjusted for dividend and other equity transactions. The maximum annual gain is limited to twice the annual base salary for the Chief Executive Officer, and the equivalent to the annual base salary for the other option holders. At least 50% of the proceeds after tax must be used to purchase shares in the company, and the purchased shares will be locked for a period of three years. The members o
Indkaldelse til ordinær generalforsamling i NKT27.2.2024 12:04:01 CET | pressemeddelelse
Selskabsmeddelelse 27. februar 2024 Meddelelse nr. 4 Indkaldelse til ordinær generalforsamling i NKT NKT A/S indkalder til ordinær generalforsamling onsdag den 20. marts 2024 kl. 15.00 (CET), hvor dørene åbner fra kl. 14.30 (CET) på Glostrup Park Hotel, Hovedvejen 41, 2600 Glostrup. Årsrapport, invitation og dagsorden med de fuldstændige forslag inklusive bilag og oversigt over bestyrelseskandidater er vedhæftet. Mere information kan findes på investors.nkt.com/generalforsamling. NKT’s Årsrapport, Bæredygtighedsrapport og Vederlagsrapport for 2023 kan også læses og printes på investors.nkt.com/corporate-governance/statutory-reports. Kontakt Investor Relations: Michael Nass Nielsen, Head of Investor Relations, Tlf: +45 2494 1654 Presse: Pelle Fischer, External Communications Lead, Tlf: +45 2223 5870 Vedhæftede filer Tilmeldingsblanket 2024Bestyrelseskandidater_2024-finalBilag_Vederlagspolitik 2024Dagsorden og fuldstændige forslag 2024Fuldmagt og Brevstemme 2024Invitation 2024NKT indkald
Notice convening the NKT Annual General Meeting27.2.2024 12:04:01 CET | Press release
Company Announcement 27 February 2024 Announcement No. 4 Notice convening the NKT Annual General Meeting The Annual General Meeting of NKT A/S will be held Wednesday 20 March 2024 at 3.00 p.m. (CET) with doors opening from 2.30 p.m. (CET) at Glostrup Park Hotel, Hovedvejen 41, 2600 Glostrup. Attached are the annual report, invitation and agenda with the full contents of proposals and exhibits, including overview of candidates for the Board of Directors. More information can be found at investors.nkt.com/general-meetings. The Annual Report, Sustainability Report and Remuneration Report for 2023 can be found and printed at investors.nkt.com/corporate-governance/statutory-reports. Contact Investor Relations: Michael Nass Nielsen, Head of Investor Relations, tel: +45 2494 1654 Press: Pelle Fischer, External Communications Lead, tel. +45 2223 5870 Attachments NKT_Annual_Report_2023NKT_Remuneration_Report_2023nkt-2023-12-31-enNotice convening the NKT Annual General Meeting 2024Proxy and post
Zymeworks Announces Participation in Upcoming Investor Conferences27.2.2024 12:00:00 CET | Press release
VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: TD Cowen 44th Annual Health Care Conference: Zymeworks’ management will participate in one-on-one meetings and present on March 6th at 11:10 am Eastern Time (ET) in Boston, MA.Barclays 26th Annual Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on March 14th at 11:45 am ET in Miami, FL. All presentations and webcasts will be available on Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations. About Zymeworks Inc. Zymeworks is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional bio
Philips launches new Azurion neuro biplane system at #ECR2024 to speed up and improve minimally invasive diagnosis and treatment of neurovascular patients27.2.2024 12:00:00 CET | Press release
February 27, 2024 New image-guided therapy system is a complete interventional solution for confident diagnosis, image guidance, and therapy assessment of patients with stroke or other neurovascular diseases Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced major enhancements to its Image Guided Therapy System – Azurion – with the launch of its new Azurion neuro biplane system. Designed to streamline neurovascular procedures and help care teams make the right decisions faster, treat more patients, and achieve better outcomes, the new interventional system features enhanced 2D and 3D imaging and X-ray detector positioning flexibility. As healthcare providers strive to deliver high-quality care to patients, at #ECR2024 Philips is partnering with its customers to improve productivity and access to more sustainable healthcare. Minimally invasive procedures enabled by interventional systems like Azurion are a key part of